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Comparisons between diﬀ erent polychemotherapy 
regimens for early breast cancer: meta-analyses of long-term 
outcome among 100 000 women in 123 randomised trials
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Summary
Background Moderate diﬀ erences in eﬃ  cacy between adjuvant chemotherapy regimens for breast cancer are plausible, 
and could aﬀ ect treatment choices. We sought any such diﬀ erences.
Methods We undertook individual-patient-data meta-analyses of the randomised trials comparing: any taxane-plus-
anthracycline-based regimen versus the same, or more, non-taxane chemotherapy (n=44 000); one anthracycline-
based regimen versus another (n=7000) or versus cyclo phosphamide, methotrexate, and ﬂ uorouracil (CMF; n=18 000); 
and polychemotherapy versus no chemotherapy (n=32 000). The scheduled dosages of these three drugs and of the 
anthracyclines doxorubicin (A) and epirubicin (E) were used to deﬁ ne standard CMF, standard 4AC, and CAF and 
CEF. Log-rank breast cancer mortality rate ratios (RRs) are reported.
Findings In trials adding four separate cycles of a taxane to a ﬁ xed anthracycline-based control regimen, extending 
treatment duration, breast cancer mortality was reduced (RR 0·86, SE 0·04, two-sided signiﬁ cance [2p]=0·0005). In 
trials with four such extra cycles of a taxane counterbalanced in controls by extra cycles of other cytotoxic drugs, roughly 
doubling non-taxane dosage, there was no signiﬁ cant diﬀ erence (RR 0·94, SE 0·06, 2p=0·33). Trials with CMF-treated 
controls showed that standard 4AC and standard CMF were equivalent (RR 0·98, SE 0·05, 2p=0·67), but that 
anthracycline-based regi mens with substantially higher cumulative dosage than standard 4AC (eg, CAF or CEF) were 
superior to standard CMF (RR 0·78, SE 0·06, 2p=0·0004). Trials versus no chemotherapy also suggested greater 
mortality reductions with CAF (RR 0·64, SE 0·09, 2p<0·0001) than with standard 4AC (RR 0·78, SE 0·09, 2p=0·01) or 
standard CMF (RR 0·76, SE 0·05, 2p<0·0001). In all meta-analyses involving taxane-based or anthracycline-based 
regimens, proportional risk reductions were little aﬀ ected by age, nodal status, tumour diameter or diﬀ erentiation 
(moderate or poor; few were well diﬀ erentiated), oestrogen receptor status, or tamoxifen use. Hence, largely 
independently of age (up to at least 70 years) or the tumour characteristics currently available to us for the patients 
selected to be in these trials, some taxane-plus-anthracycline-based or higher-cumulative-dosage anthracycline-based 
regimens (not requiring stem cells) reduced breast cancer mortality by, on average, about one-third. 10-year overall 
mortality diﬀ erences paralleled breast cancer mortality diﬀ erences, despite taxane, anthracycline, and other toxicities.
Interpretation 10-year gains from a one-third breast cancer mortality reduction depend on absolute risks without 
chemotherapy (which, for oestrogen-receptor-positive disease, are the risks remaining with appropriate endocrine 
therapy). Low absolute risk implies low absolute beneﬁ t, but information was lacking about tumour gene expression 
markers or quantitative immunohistochemistry that might help to predict risk, chemosensitivity, or both.
Funding Cancer Research UK; British Heart Foundation; UK Medical Research Council.
Introduction
The Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG) was established in 1985 to coordinate 
individual-patient-level meta-analyses of all random ised 
trials of adjuvant treatments.1–4 A previous report1 on the 
trials that had begun by 1995 reviewed polychemotherapy 
ver sus no adjuvant chemotherapy and anthracycline-
based chemotherapy (with doxorubicin or epirubicin) 
versus CMF (cyclophosphamide, methotrexate, ﬂ uorour-
acil), but did not take dosage into account and did not 
review taxanes. 
The present report reviews the preliminary taxane trial 
results and updates the other chemotherapy trial results, 
assessing the relevance of scheduled drug dosage and 
investigating whether any of the available patient or 
tumour characteristics (eg, age, nodal status, tumour 
diﬀ erentiation, oestrogen receptor [ER] status, use of 
tamoxifen) aﬀ ect the proportional reductions with modern 
chemotherapy in breast cancer recurrence and death.
Methods
Trials
Methods of trial identiﬁ cation, data checking, analysis, 
and involvement of trialists in the interpretation of 
results are as in previous EBCTCG reports.1–4 Information 
about each individual patient was sought during 2005–10 
from all randomised trials begun during 1973–2003 of: 
(1) taxane-based versus non-taxane-based regimens (data 
for 33 trials, begun in 1994–2003); (2) any anthracycline-
based regimen versus standard or near-standard CMF 
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(see table for the terminology used for these and selected 
other regimens; 20 trials, begun in 1978–97); (3) higher 
versus lower anthracycline dosage (six trials, begun in 
1985–94); and (4) polychemotherapy versus no adjuvant 
chemotherapy (64 trials, begun in 1973–96, including 
22 of various anthra cycline-based regimens and 12 of 
standard or near-standard CMF). 
Trials of intensive chemotherapy with stem-cell rescue 
or of variation only in dose-density are not included. 
Datasets from taxane trials had to await trial publication, 
so they arrived from 2005 to 2010; although 33 are 
included (n=45 000), three are not (n=7000; started by 
2003 and unreported before mid-2010; see forest plot in 
webappendix p 23). Otherwise, all main analyses include 
99% or more of all relevant patients in closed trials.
Statistical analysis
For each main chemotherapy comparison, forest plots 
(webappendix pp 21–62) describe the separate trials and 
their results, graphs illustrate absolute risks in various 
circumstances, and detailed subgroup analyses explore 
whether proportional risk reductions depend on patient 
or tumour charac teristics. All text ﬁ gures plus many 
more detailed analyses, and trial references, are in the 
webappendix (which needs magniﬁ ed viewing).
Recurrence, ER, and nodal status are deﬁ ned as before.4 
Statistical analyses are stratiﬁ ed as before4 by trial, age, 
ER status, and, except in neoadjuvant trials, nodal status. 
If a log-rank statistic (o − e) has variance v, then, deﬁ ning 
z = (o − e) / √v and b = (o − e) / v, the event rate ratio (RR, 
newer treatment vs control) is estimated as exp(b) with 
standard error SE = (RR − 1) / z. Either RR and its SE are 
cited, or conﬁ dence limits for RR are derived from those 
for b (by normal approximations). 2p indicates two-sided 
signiﬁ  cance, and n the number of patients to the nearest 
500 or 1000 (with, for balance, control groups that were 
compared with more than one active group double-
counted or triple-counted).
Breast cancer mortality rate in each year is the overall 
mortality rate among all women minus that among 
women without recurrence. Breast cancer mortality RRs 
are estimated from the corresponding log-rank analyses 
of mortality with recurrence (obtained by subtracting 
log-rank analyses of mortality without recurrence 
[ie, censored at recurrence] from those of overall 
mortality; web appendix p 1). For indirect comparisons 
between diﬀ erent regimens, eﬀ ects on early recurrence 
rates (years 0–4) might be more sensitive than eﬀ ects on 
other outcomes, because they are substantial and not 
materially aﬀ ected by diﬀ erences in follow-up duration 
(or chance eﬀ ects on recurrence rates in later years when 
proportional reductions might be less extreme than in 
years 0–4), so the webappendix reports eﬀ ects on early 
recurrence, any recurrence, and mortality.
For at least some major subgroup analyses to be 
statistically reliable, the overall χ²₁ for the RR (treatment 
vs control) in all subgroups together should generally be 
large (eg, at least 25, but preferably 50, or even 100). For, if 
there is little real heterogeneity between the RRs, this 
overall χ²₁ (plus the small χ² for heterogeneity between 
treatment RRs in diﬀ erent subgroups) gets partitioned 
between the subgroups in approximate proportion to 
numbers of events, to yield χ²₁ in each. If χ²₁ in a major 
subgroup should be only about 10 or less after such a 
split, chance could well make it non-signiﬁ cant or null.6 
For, a subgroup-speciﬁ c treatment eﬀ ect that, given the 
overall ﬁ ndings, should be about 3 SE (yielding χ²₁=9, 
2p=0·003) could easily by chance be less than 
2SE (and hence not signiﬁ cant). Statistical analyses 
utilised programs written by the EBCTCG in FORTRAN.
Role of the funding sources
The funders had no role in study design, conduct, or 
reporting. The Secretariat had full access to all data. The 
decision to publish was by the writing committee, after 
circulation to all collaborators.
Results
Taxane-based regimens versus active controls
For each trial of taxane-based versus non-taxane-based 
chemotherapy, forest plots (webappendix pp 21–26) give 
results for early recurrence (years 0–4), any recurrence, 
breast cancer mortality (mortality with recurrence, by 
log-rank subtraction), mortality without recurrence (ﬁ rst 
year only, all years), and overall mortality. Each forest plot 
gives one line per trial: year started, study name, regimens 
compared, results, and log-rank analyses.
Treatment comparisons varied greatly, which compli-
cates meta-analyses. All but two trials (excluded from the 
meta-analyses) compared a taxane-plus-anthracycline-
based regimen versus an anthracycline-based control 
regimen with the same or more of each non-taxane 
component. Averaging the results for all such trials to test 
for some taxane eﬀ ect (by summing the trial-speciﬁ c log-
rank statistics; webappendix pp 7–8 and 21–26; n=44 000), 
the RRs were 0·87 (SE 0·03) for distant recurrence, 0·86 
(SE 0·02, χ²₁=47·7, 2p<0·00001) for any recurrence, 0·87 
(SE 0·03, χ²₁=22·0, 2p<0·00001) for breast cancer 
mortality, 0·99 (SE 0·08, no net hazard) for other mortality, 
and 0·89 (SE 0·03, 2p<0·00001) for overall mortality.
See Online for webappendix
Scheduled number of cycles and cytotoxic treatment per cycle
Standard CMF 6 cycles of C100×14 M40×2 F500×2, given 4-weekly; widely studied
Near-standard CMF5 6–12 cycles with same doses as standard CMF and/or C600×2 replacing C100×14
Standard 4AC 4 cycles of A60 C600, given iv 3-weekly; widely studied
Standard 4EC 4 cycles of E90 C600, given iv 3-weekly
CAF 6 cycles of C100×14 A30×2 F500×2, given 4-weekly
CEF 6 cycles of C75×14 E60×2 F500×2, given 4-weekly
Data are drug dose, mg/m²×frequency per cycle (×14=days 1–14 oral; ×2=days 1 and 8 iv). Tabulated treatment 
schedules do not include any supportive care or cytotoxic dose reduction for acute toxicity. C=cyclophosphamide. 
M=methotrexate. F=ﬂ uorouracil. A=doxorubicin (Adriamycin). E=epirubicin. iv=intravenous.
Table: Terminology—standard regimens and higher-cumulative-dose regimens
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These varied treatment comparisons can be grouped by 
how the chemo therapy regimen in the control group 
compared with the non-taxane chemotherapy in the taxane 
group: the same (ie, unconfounded trials of the eﬀ ects of 
adding four separate cycles just of a taxane to a constant 
background chemotherapy regimen, thereby prolonging 
treatment duration; n=11 000), double (ie, strongly con-
founded trials in which the eﬀ ects of adding four separate 
cycles of a taxane to an anthracycline-based regimen were 
counterbalanced in controls by roughly doubling the 
number of cycles of non-taxane chemo therapy; n=10 000), 
or inter mediate (n=23 000). Only in some of the trials with 
an intermediate control regimen was the taxane given 
concurrently with any other cytotoxic agents.
In the unconfounded taxane trials, which all 
began in 1994–99, little follow-up beyond year 8 is yet 
available; ﬁ gure 1 (left-hand side) gives absolute eﬀ ects on 
8-year recurrence, breast mortality, and overall mortality 
in these trials. Eﬀ ects were moderate for recurrence, and 
slightly smaller (but still highly signiﬁ cant) for breast 
cancer mortality and overall mortality. 8-year breast cancer 
mortality was 21·1% for the taxane groups versus 23·9% 
for the control groups (absolute gain 2·8%, SE 0·9; 
RR 0·86, SE 0·04, 2p=0·0005); for overall mortality the 
absolute gain was similar. By contrast, in the trials of 
adding four cycles of a taxane versus roughly doubling 
the non-taxane chemotherapy, there was little net 
diﬀ erence in recurrence, breast cancer mortality (foot of 
ﬁ gure 2A; n=10 000; RR 0·94, SE 0·06, 2p=0·16), or 
overall mor tality (webappendix pp 7–8 and 21–26); again, 
however, comparisons varied, and follow-up was short.
Figure 1 (right-hand side) describes these and all 
other trials in which the eﬀ ects of the taxane were 
counterbalanced by giving the controls more non-taxane 
chemotherapy (n=33 000 with data on numbers dead in 
each treatment group, only 30 000 of whom had data on 
the times to any deaths; webappendix p 23). In these 
confounded taxane trials, little follow-up beyond 5 years is 
yet available, but on average their 5-year ﬁ ndings again 
show small but signiﬁ cant reductions in recurrence, 
breast cancer mortality, and overall mortality. Chemo-
therapy regimens varied greatly, so real treatment eﬀ ects 
in diﬀ erent trials could well diﬀ er, even though chance 
makes it diﬃ  cult to assess this reliably, particularly with 
short follow-up and some trials not yet available. Only one 
trial (GEICAM99067) involved weekly paclitaxel.
Figure 2 shows selected subgroup analyses for breast 
cancer mortality in all 44 000 women. Its ﬁ rst three sections 
group the treatment comparisons in various ways, without 
Figure 1: Time to recurrence, breast cancer mortality, and overall mortality 
for taxane-plus-anthracycline-based regimens (Tax+anth) versus control 
with (left) the same or (right) more non-taxane chemotherapy
Trials versus the same non-taxane chemotherapy (usually 4AC) just added 
four extra taxane-only cycles. RR (and its 95% CI)=event rate ratio, from 
summed log-rank statistics for all time periods combined. Gain (and its 
SE)=absolute diﬀ erence between ends of graphs. Event rates, %/year, are 
followed by (ﬁ rst events/woman-years). Error bars show ±1 SE.
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ﬁ nding clear evidence of diﬀ erences in the average 
treatment eﬀ ect. Its ﬁ rst section groups the taxane 
comparisons as unconfounded, intermediate, or strongly 
confounded, as above (for the trial-speciﬁ c details 
corresponding to these groupings see webappendix 
pp 21–26) and the next two sections group the treatment 
Figure 2: Subgroup analyses of breast cancer mortality (mortality with recurrence, by log-rank subtraction) for taxane-plus-anthracycline-based regimens 
versus the same, or more (less than doubled or roughly doubled), non-taxane cytotoxic chemotherapy
D=docetaxel. P=paclitaxel. 4(D100) q3w=four doses of docetaxel 100 mg/m² at intervals of 3 weeks. 4(P175) q3w=four doses of paclitaxel 175 mg/m² at intervals of 
3 weeks. ER=oestrogen receptor. NS=not signiﬁ cant. *First four subgroups are as in the forest plots (webappendix pp 21−26) that give details of each trial’s cytotoxic 
regimens. †Taxane courses do not overlap other chemotherapy courses. ‡Taxane given concurrently with anthracycline.
(A)  Same, or more, non-taxane chemotherapy for controls* (χ2=2·0; p=0·6; NS)
Same (1×)† (ie, unconfounded)
More (<2×)†
More (<2×)‡
More (=2×)†
(B)  Taxane (D/P*) schedule (χ2=1·0; p=0·8; NS)
4(D100) q3w†
Other docetaxel
4(P175) q3w†
Other paclitaxel
(C)  Concurrent endocrine therapy (if ER+)? (χ2=0·2; 2p=0·6; NS)
Yes
No (any endocrine only after chemotherapy ended)
(D)  Entry age (trend χ2=3·5; 2p=0·06)
<45 years
45–54 years
55–69 years
>70 years
Unknown
(E)  Nodal status before chemotherapy (trend χ2=0·3; 2p=0·6; NS)
N0/N–
N1–3
N4+
Other/unknown
(F)  ER status (χ2=0·1; 2p=0·7; NS)
ER–poor
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ER+, well diﬀerentiated
Total
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 835/7747 (10·8%)
 735/6572 (11·2%)
 51/314 (16·2%)
 149/1565 (9·5%)
 120/2104 (5·7%)
 520/6981 (7·4%)
 783/5012 (15·6%)
 1218/8031 (15·2%)
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comparisons in other ways. Later sections, again without 
clear evidence of heterogeneity of treatment eﬀ ect, 
subdivide by age (ﬁ nding signiﬁ cant beneﬁ t even at ages 
55–69 years; few were older, but their results suggest 
favourable eﬀ ects of taxanes even in old age), nodal status 
before chemotherapy (4000 had node-negative disease), 
and ER status. Results are also given for subsets of ER-
positive disease by HER2 status (generally by immuno-
histo chemistry, classiﬁ ed where possible by standard 
criteria for deﬁ nite positivity8), age, and diﬀ erentiation 
(with a trend towards greater taxane beneﬁ t in well 
diﬀ erentiated [RR 0·68, SE 0·16, 2p=0·04, n=3000] or 
moderately diﬀ erentiated [RR 0·77, SE 0·07, 2p=0·001, 
n=11 000] ER-positive tumours than in poorly diﬀ erentiated 
ER-positive tumours). Most of the women with ER-positive 
disease had endocrine therapy after their chemotherapy.
More detailed subgroup analyses of recurrence and 
breast cancer mortality (webappendix pp 7–8) found no 
consistent heterogeneity of the proportional risk 
reductions by age, nodal status, ER status, progesterone 
receptor status, tumour diﬀ erentiation (although only 
4000 were well diﬀ erentiated; webappendix p 8), tumour 
diameter, or combin ations of these. Proportional risk 
reductions appeared similar in years 0–1, 2–4, and 
(provisionally) 5+ after entry, so the indirect treatment 
comparisons in ﬁ gure 2 should not have been materially 
aﬀ ected by diﬀ erences between taxane trials in follow-
up duration. If there is real heterogeneity between 
eﬀ ects in diﬀ erent subgroups, this should be clearer for 
recurrence (overall χ²₁=48) than for breast cancer 
mortality (overall χ²₁=22), but neither χ² value is big 
enough for subgroup analyses to be wholly reliable.
Anthracycline-based regimens versus active controls
For trials of an anthracycline-based regimen versus CMF, 
forest plots for each of several diﬀ erent outcomes 
(webappendix pp 27–32) give one descriptive line per 
trial: name, regimens compared, and results. The control 
regimen was generally standard CMF (otherwise it was 
near-standard CMF; to challenge anthra cycline-based 
regimens rigorously, however, these analyses exclude 
CMF regimens with the dose per cycle of any drug less 
than that in near-standard CMF; see table). Again, most 
of the women with ER-positive disease would have been 
given endocrine therapy after their chemotherapy.
Figure 3 (left-hand side; n=9500) shows results from 
the trials with anthracycline dose per cycle at least 
60 mg/m² doxorubicin or 90 mg/m² epirubicin and with 
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Figure 3: Time to recurrence, breast cancer mortality, and overall mortality for 
selected anthracycline-based regimens versus standard or near-standard CMF
Left: regimens with cumulative dosage greater than 240 mg/m² doxorubicin or 
360 mg/m² epirubicin (eg, CAF or CEF). Right: standard 4AC (cumulative dosage 
240 mg/m² doxorubicin). All graphs exclude regimens with less than 60 mg/m² 
doxorubicin or 90 mg/m² epirubicin per cycle. RR (and its 95% CI)=event rate 
ratio, from summed log-rank statistics for all time periods combined. Gain (and 
its SE)=absolute diﬀ erence between ends of graphs. Anth=anthracycline. Event 
rates, %/year, are followed by (ﬁ rst events/woman-years). Error bars show ±1 SE.
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cumulative anthracycline dosage more than 240 mg/m² 
doxorubicin or 360 mg/m² epirubicin (eg, CAF or CEF). 
The ﬁ ndings for recurrence, breast cancer mortality, and 
overall mortality show a deﬁ nite improvement over CMF. 
Averaging the results for all these trials, the RRs were 
0·89 for recurrence (SE 0·04, 2p=0·003; this included 
what might have been mainly a chance excess incidence 
of contralateral disease), 0·80 for breast cancer mortality 
(SE 0·05, 2p=0·00001), and 0·84 for overall mortality 
(SE 0·04, χ²₁=9·9, 2p=0·0002). By contrast, standard 4AC 
and standard CMF appeared equivalent (right-hand side 
of ﬁ gure 3; n=5000).
Figure 4: Subgroup analyses of breast cancer mortality (mortality with recurrence, by log-rank subtraction) for any anthracycline-based regimen versus 
standard CMF (or near-standard CMF)
A=doxorubicin (Adriamycin). E=epirubicin. Dose/cycle (and cumulative dosage) is given after the drug name in mg/m²; A60/E90 means 60 mg/m² of doxorubicin or 
90 mg/m² of epirubicin. iv=intravenous. NS=not signiﬁ cant. ER=oestrogen receptor. IHC=immunohistochemistry. *First four subgroups are as in the forest plots 
(webappendix pp 27−32) that give details of each trial’s cytotoxic regimens.
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In these trials there was a signiﬁ cant trend towards 
greater eﬃ  cacy with higher cumulative anthracycline 
dosage (χ²₁=8·0, 2p=0·005; ﬁ gure 4A). This trend was not 
neces sarily due just to the extra anthracycline, however, 
because higher dosage was often accompanied by other 
additional chemotherapy (webappendix p 29). The 
regimens with the highest cumulative anthracycline 
dosage include CAF and CEF (which, like standard CMF, 
have 14 days per cycle of oral cyclophosphamide), and 
were, on average, signiﬁ cantly better than standard CMF 
at reducing breast cancer mortality (RR 0·78, SE 0·06, 
2p=0·0004; ﬁ gure 4A).
The foregoing comparisons between the eﬀ ects of 
diﬀ erent anthracycline-based regimens in diﬀ erent trials 
are indirect. Few trials have compared directly one 
anthracycline-based regimen versus another (web appendix 
pp 45–50), and their results are not yet mature. Those in 
which all drugs varied together showed signiﬁ cantly 
greater eﬃ  cacy with higher than lower dosage. Trials in 
which only the anthracycline dose per cycle varied showed, 
in aggregate, only non-signiﬁ cantly greater eﬃ  cacy; one 
compared a standard versus lower anthracycline dose per 
cycle (GFEA05:9 epirubicin 100 vs 50 mg/m² per cycle, 
n=500), ﬁ nding the standard dose signiﬁ cantly more 
eﬀ ective, and one compared a standard dose versus two 
higher anthracycline doses per cycle (CALGB9344:10 
doxorubicin 90 vs 75 vs 60 mg/m² per cycle, n=3000), 
ﬁ nding no signiﬁ cant diﬀ er ence in eﬃ  cacy between the 
highest and lowest doses. Although the latter comparison 
suggests little gain from the higher dose per cycle, the CIs 
associated with it do not preclude moderate further gain.
The anthracycline-based regimens varied greatly, so their 
average eﬀ ect underestimates the eﬀ ects of the better ones, 
and is given mainly to exclude the hypothesis that none is 
better than standard CMF and to help to assess safety. 
Averaging the results for all these trials of any anthracycline-
based regimen versus CMF (web appendix pp 9–10 and 
31–32; n=18 000), the RRs were 0·88 (SE 0·03, χ²₁=14·4, 
2p=0·0002) for distant recurrence, 0·93 (SE 0·03, χ²₁=6·5, 
2p=0·01) for any recurrence, 0·89 (SE 0·03, χ²₁=12·0, 
2p=0·0006) for breast cancer mortality, 1·02 (SE 0·09, no 
signiﬁ cant diﬀ erence) for other mortality, and 0·91 (SE 
0·03, χ²₁=9·9, 2p=0·002) for overall mortality.
Figure 4 (and webappendix pp 9–10) split the overall 
results by patient characteristics, site of ﬁ rst recurrence, 
and time period. (HER2 status was unavail able.) These 
subgroup analyses did not show heterogeneity of the 
proportional risk reduction by age, nodal status, ER status, 
ER level, or tumour diﬀ erentiation or diameter. Since, 
however, the overall χ²₁ (for the average treatment eﬀ ect 
in all patients in all trials) was only 12·0, which is too 
small for subgroup analyses to be reliable, non-signiﬁ cant 
results in any particular subgroup are uninformative.
Conversely, signiﬁ cant results in particular sub groups 
might well reﬂ ect chance exaggerations (eg, the 
anthracycline-based regimens appeared better than CMF 
only if ER status was untested; ﬁ gure 4). Likewise, chance 
in small subgroups could well explain why anthracyclines 
appeared particularly eﬀ ective for disease with ER greater 
than 100 fmol/mg cytosol protein (RR 0·69, SE 0·13, 
2p=0·02). For each subgroup, the best evidence as to 
whether particular anthracycline-based regimens are 
better than standard CMF is from the results in all 
women, ER-tested or not.6
Chemotherapy versus no-chemotherapy controls
For each trial of an anthracycline-based regimen or of 
standard or near-standard CMF versus no adjuvant 
chemotherapy, forest plots for several outcomes (web-
appendix pp 33–44) give one descriptive line per trial. 
Although these 25-year-old trials of chemotherapy versus 
not (median start date 1986, IQR 1980–90) provide some 
further evidence about the comparative eﬃ  cacy of diﬀ erent 
regimens, none studied taxanes, half gave no endocrine 
therapy, supportive care during treatment was sometimes 
suboptimal, and toxicity concerns probably limited dosage 
(since chemotherapy was of uncertain value, particularly 
for older women, when these trials were done). Finally, the 
populations in diﬀ erent trials diﬀ ered: in the anthracycline 
trials only 18% had node-negative disease (66% in the CMF 
trials) and only 11% of ﬁ rst recurrences were locoregional 
(33% in the CMF trials; details in webappendix pp 11 and 13). 
Nevertheless, these old trials versus no chemotherapy still 
have some relevance to future patients.
Figure 5 shows 10-year outcomes for any anthracycline-
based regimen versus no chemo therapy (left-hand side; 
one trial studied CAF and a few studied standard 4AC, 
but most studied regimens with a substantially lower 
anthracycline dose per cycle) and for CMF versus no 
chemotherapy (right-hand side; standard CMF or near-
standard CMF). In both cases the main recurrence 
reductions were during years 0–4, but for breast cancer 
mortality there were gains throughout the ﬁ rst decade. 
During years 0–4, the absolute eﬀ ects on breast cancer 
mortality and on overall mortality were similar, suggesting 
little net adverse eﬀ ect on other mortality, but later non-
breast-cancer mortality was somewhat greater with 
chemo therapy, although 10-year overall mortality was still 
reduced (webappendix pp 42–44). Further follow-up is 
needed of longer-term eﬀ ects on breast cancer mortality, 
on other mortality, and on overall mortality.
For any anthracycline-based regimen versus no 
chemotherapy (ﬁ gure 5; webappendix pp 11 and 37; 
n=8500), RRs were 0·69 (SE 0·04) for distant recurrence, 
0·73 (SE 0·03, χ²₁=70·3) for any recurrence, 0·79 (SE 0·04, 
χ²₁=33·7) for breast cancer mortality, 1·20 (SE 0·10, 
2p=0·05 for increase) for other mortality, and 0·84 
(SE 0·03, 2p<0·00001) for overall mortality. Several 
diﬀ erent regimens were tested. For CMF versus no 
chemotherapy (ﬁ gure 5; webappendix pp 13 and 43; 
n=5000), RRs were 0·66 (SE 0·05) for distant recurrence, 
0·70 (SE 0·04, χ²₁=55·6) for any recurrence, 0·76 (SE 0·05, 
χ²₁=24·8, 2p<0·00001) for breast cancer mortality, 
1·24 (SE 0·12, 2p=0·05 for increase) for other mortality, 
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and 0·84 (SE 0·05, 2p=0·0004) for overall mortality. Most 
of these trials studied standard CMF (and the remainder 
studied near-standard CMF; see table).
Treatment eﬀ ects are larger for chemotherapy versus 
no chemotherapy than for one type of chemotherapy 
versus another, and because the χ² values for the overall 
eﬀ ects are fairly large, the ﬁ ndings in some major 
subgroups could be informative. In the webappendix 
(pp 11–14), the ﬁ ndings for early recurrence (years 0–4), 
any recurrence, and breast cancer mortality are split by 
treatment schedule, detailed patient characteristics, site 
of ﬁ rst recurrence, and time period. For anthracycline-
based regimens, there was no good evidence of any 
heterogeneity of the proportional risk reductions with 
age, nodal status, ER status, tumour diﬀ erentiation, 
tumour diameter, or combinations of these. 
Figure 6 gives some of these subgroup analyses for 
anthracycline-based regimens. By contrast with ﬁ gure 4, 
few trials had 60 mg/m² doxorubicin per cycle or 
90 mg/m² epirubicin per cycle. Most that did studied CAF 
(SWOG8814,11 n=1500 [allocated in 3:1 ratio]) or standard 
4AC (n=1500). Although the diﬀ erence between the 
apparent eﬀ ects of these two regimens was not signiﬁ cant, 
CAF (RR 0·64, SE 0·09) appeared somewhat more 
eﬀ ective than standard 4AC or 4EC (RR 0·78, SE 0·09). 
The other regimens, all with lower anthracycline dose per 
cycle (but, in some, additional other drugs), appeared, on 
average, almost as eﬀ ective (RR 0·82, SE 0·05) as standard 
4AC. Taking all these trials of anthracycline-based 
regimens together, the average eﬀ ect approximated that 
of standard 4AC (or of standard CMF).
The proportional risk reductions appeared similar in 
trials of chemotherapy versus no adjuvant therapy and 
in trials of chemotherapy and tamoxifen (generally 
started concurrently) versus tamoxifen alone (ﬁ gure 6C), 
suggesting that chemotherapy eﬀ ects and tamoxifen 
eﬀ ects are largely independent. Supporting this ﬁ nding, 
in ER-positive disease the proportional risk reductions 
produced by tamoxifen appeared similar in trials of 
tamoxifen versus no adjuvant therapy and in trials of 
chemotherapy plus tamoxifen (started concurrently) 
versus chemotherapy alone.4 In addition to these indirect 
comparisons, there are four directly randomised 
com parisons of concurrent versus sequential chemo-
endocrine therapy,11–14 but some were not available to us.
In ﬁ gure 6 (and webappendix pp 11–12), the propor tional 
eﬀ ects of anthracycline-based regimens on breast cancer 
outcomes did not depend much on age, nodal status, 
ER status, or, if ER-positive, on endocrine therapy, 
age, nodal status, tumour diﬀ erentiation, or ER level 
Figure 5: Time to recurrence, breast cancer mortality, and overall mortality 
for chemotherapy versus no adjuvant chemotherapy
Left: four or more cycles of any anthracycline (Anth)-based regimen—eg, standard 
4AC. Right: standard or near-standard CMF. RR (and its 95% CI)=event rate ratio, 
from summed log-rank statistics for all time periods combined. Gain (and 
its SE)=absolute diﬀ erence between ends of graphs. CTX=chemotherapy.  Event 
rates, %/year, are followed by (ﬁ rst events/woman-years). Error bars show ±1 SE.
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(10–99 or >100 fmol/mg). This ﬁ nding suggests that the 
extreme RR in ﬁ gure 4 for disease with ER greater than 
100 fmol/mg could be partly a chance subgroup ﬁ nding. 
Combination of the breast cancer mortality results for 
disease with ER greater than 100 fmol/mg for any 
anthra cycline-based regimen versus no chemotherapy and 
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Figure 6: Subgroup analyses of breast cancer mortality (mortality with recurrence, by log-rank subtraction) for any anthracycline-based regimen versus 
no chemotherapy
A=doxorubicin (Adriamycin). E=epirubicin. Dose/cycle (and cumulative dosage) is given after the drug name in mg/m²; A60/E90 means 60 mg/m² of doxorubicin or 
90 mg/m² of epirubicin. NS=not signiﬁ cant. ER=oestrogen receptor. *First four subgroups are as in the forest plots (webappendix pp 33−38) that give details of each trial’s 
cytotoxic regimens. †In the SWOG 8814 trial of CAF in postmenopausal ER+ disease, tamoxifen started randomly with or after the chemotherapy.
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versus CMF chemotherapy (ﬁ gures 4 and 6) yields an RR 
of 0·77 (SE 0·07, 2p=0·002, n=3000), conﬁ rm ing at least 
some beneﬁ t of anthracycline-based regimens in this high-
ER sub group. Most women were aged 55–69 years at entry; 
results in the few who were older also suggest beneﬁ t (as 
in the taxane trials), but with wide uncertainty.
Figure 7 shows 10-year breast cancer mortality in trials of 
anthracycline-based regimens by age and ER status. The 
lack of apparent relevance of age or ER to the proportional 
risk reduction is somewhat confounded by regimen; 
almost half the evidence in older women with ER-positive 
disease (RR 0·78, SE 0·06, 2p=0·0002, n=4000) came from 
the one trial (SWOG881411) of CAF in 1500 postmenopausal 
women with tamoxifen-treated ER-positive disease, which 
showed that such chemotherapy substantially reduces 
breast cancer mortality in this major patient category.
In subgroup analyses for trials of standard or near-
standard CMF versus no chemotherapy (webappendix 
pp 13–14) the proportional risk reduction appeared 
inversely related to age and nodal status, but again 
appeared independent of ER status (RR for breast cancer 
mortality 0·80, SE 0·10, 2p=0·05 for ER-poor disease 
and 0·74, SE 0·07, 2p=0·0002 for ER-positive disease).
Among both older and younger women with ER-positive 
disease, the eﬀ ects of chemotherapy added to those of 
eﬀ ective endocrine therapy. Combining (web appendix p 6, 
ﬁ nal section) these trials of CMF and the trials of 
anthracycline-based chemotherapy versus no chemo-
therapy, if both groups had 5 years of endocrine therapy 
then chemotherapy reduced breast cancer mortality both 
in women with entry age 55–69 years (chemoendocrine vs 
only endocrine therapy, RR 0·78, SE 0·07, 2p=0·001, 
n=3000) and in younger women (RR 0·72, SE 0·09, 
2p=0·002, n=2000). Of these younger women, half were 
known to be premenopausal or perimenopausal (with RR 
0·76, SE 0·13, 2p=0·06, n=1000), but information about 
chemotherapy-induced amenorrhoea was unavailable.
To help assess any life-threatening acute toxicity, the 
table on webappendix p 63 describes 1-year mortality 
without recurrence. In trials comparing two active 
regimens, this early mortality depended less on treatment 
group than on age, and before age 70 years it was relatively 
low (eg, 59/19 477 [0·3%] for taxane-plus-anthracycline-
based regimens vs 40/19 386 [0·2%] for anthracycline-
based control regimens, 2p=0·06). In trials of 
chemo therapy versus no chemotherapy, these 1-year 
hazards were notable only in the 1970s trials of 12 cycles 
of CMF and in one of the two trials11,15 of CAF.
There were also, as expected,16–18 some deaths from acute 
myeloid leukaemia and anthracycline cardiotoxicity. 
Figure 7: At least four cycles of any anthracycline-based regimen (with mean 
eﬀ ect roughly as for standard 4AC) versus no adjuvant chemotherapy: 
analyses of 10-year breast cancer mortality by age and ER status
RR (and its 95% CI)=event rate ratio, from summed log-rank statistics for all 
time periods combined. Gain (and its SE)=absolute diﬀ erence between ends of 
graphs. ER=oestrogen receptor. Anth=anthracycline. Event rates, %/year, are 
followed by (ﬁ rst events/woman-years). Error bars show ±1 SE
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Numbers of acute myeloid leukaemia deaths without 
recurrence were 11 versus one for taxane plus other 
chemotherapy versus the same, or more, other chemo-
therapy; ﬁ ve each for anthracycline versus CMF; eight 
versus none for anthracycline versus nil; and one 
versus three for CMF versus nil. These excesses were 
mainly with two regimens: 225 mg/m²/cycle paclitaxel 
(7/1531 [0·5%] in the only trial) and CAF (5/2638 [0·2%] in 
one trial and 2/1177 [0·2%] in the other). Undue emphasis 
on particular regimens can, however, exaggerate any real 
hazards, some trials did not report causes of death, and 
eﬀ ective follow-up duration diﬀ ers greatly in diﬀ erent 
trials. Cardiac mortality RRs for any anthracycline-based 
regimen were 1·50 (SE 0·38) versus CMF, 1·61 (SE 0·31) 
versus nil, and 1·56 (SE 0·24, 2p=0·02) versus either. 
There were no other signiﬁ cant adverse eﬀ ects on 10-year 
non-breast cancer mortality, and overall mortality always 
matched breast cancer mortality (webappendix pp 18–20).
Powerpoints of all ﬁ gures conclude the webappendix.
Discussion
These meta-analyses yield ﬁ ve main ﬁ ndings. First, 
standard CMF and standard 4AC were roughly equiva lent: 
with either, 2-year recurrence rates were halved, recurrence 
rates during the next 8 years were reduced by one-third, 
and breast cancer mortality rates were reduced by 20–25%. 
Second, regimens with signiﬁ cantly lower dose per cycle 
appeared, collectively, somewhat less eﬀ ective. Third, 
regimens with substantially more chemotherapy than 
standard 4AC (but not so intensive as to require stem-cell 
rescue) were somewhat more eﬀ ective: in comparisons 
versus standard CMF or 4AC, a further propor tional 
reduction of 15–20% in breast cancer mortality rates could 
be achieved by regimens such as CAF11,15 or CEF19 or by 
regimens such as 4AC plus four cycles of taxane (given 
3-weekly; weekly paclitaxel may be promising,7,20 but was 
little studied). Reconciling reports of major beneﬁ t and no 
extra beneﬁ t in particular taxane trials, on average the 
taxane-plus-anthracycline-based regimens slightly but 
signiﬁ cantly improved outcome in comparison with an 
anthracycline-based control regimen (unless the taxane 
was counterbalanced in controls by roughly doubling the 
number of courses of other cytotoxic drugs). Fourth, in all 
chemotherapy comparisons 10-year overall mortality was 
correspondingly reduced since there was little excess non-
breast-cancer mortality during the ﬁ rst year (partly because 
many patients got appropriate supportive care with, 
for some, substantial dose reductions to limit 
acute toxicity19) or after it.
Multiplying together breast cancer mortality RRs for 
the ﬁ rst and third of these ﬁ ndings (standard CMF or 
standard 4AC vs no chemotherapy, and more eﬀ ective 
regimens vs either of these; 0·775 × 0·825 = 0·64) would 
suggest about 36% breast cancer mortality rate reduction 
for the more eﬀ ective regimens versus no chemotherapy. 
Although proportional reductions are slightly smaller for 
10-year risks than for mortality rates (eg, a 36% reduction 
in the death rate in each year would reduce a 10-year risk 
of 30% to 20%), this calculation still suggests that the 
10-year risk of death from breast cancer can be reduced 
by about a third, averaging over the diﬀ erent types of 
patient in these trials.
Finally, in all meta-analyses involving taxane-based 
regimens or anthracycline-based regimens, the propor-
tional reductions in early recurrence, any recurrence, and 
breast cancer mortality appeared largely independent of 
age, nodal status, tumour diameter, tumour diﬀ erentiation 
(poorly or moderately diﬀ erentiated; relatively few were 
well diﬀ erentiated), or ER status (ER-poor or ER-positive). 
Even in strongly ER-positive disease, chemotherapy did 
at least somewhat aﬀ ect outcome, although not neces-
sarily to exactly the same extent as in less strongly ER-
positive disease.21,22 
In premenopausal women chemotherapy generally 
causes permanent or transient amenorrhoea, and this 
suppression of ovarian function accounts for some of its 
eﬃ  cacy in ER-positive disease.23,24 Chemotherapy must, 
however, have had additional eﬀ ects on outcome in some 
women with ER-positive disease, since chemoendocrine 
therapy produced a sub stantially greater proportional 
reduction in breast cancer mortality than did endocrine 
therapy alone (or chemotherapy alone4) not only in women 
under 55 years of age but also in older women, in whom 
chemotherapy-induced amenorrhoea is irrelevant.11 
Although age did not much aﬀ ect the proportional risk 
reductions with taxane-based or anthracycline-based 
chemotherapy, the gain in life expectancy from a given 
absolute reduction in the risk of death from breast cancer 
is greater for younger than for older women, as more years 
are lost by death at 50 than at 70 years of age. Few women 
over 70 years of age entered these trials; they may have had 
somewhat greater imme di ate hazards from chemotherapy, 
but appear to have had as great a reduction as younger 
women in breast cancer recurrence and mortality.
A pathological complete response to neoadjuvant 
chemo therapy is more likely with ER-negative than with 
ER-positive tumours, and it has been suggested that ER 
status can in certain circumstances aﬀ ect the proportional 
risk reduction with adjuvant chemotherapy.26–28 Yet, in 
these meta-analyses the proportional reductions in breast 
cancer recurrence and  mortality with adjuvant chemo-
therapy were roughly independent of ER status (and, in 
ER-positive disease, of age and of the other avail-
able tumour characteristics). Although not centrally 
remeasured, the ER measurements were good enough for 
ER status to predict both tamoxifen responsiveness4 and 
risk during years 0–1 (which was much greater in ER-poor 
than in ER-positive disease). Thus, there is no good reason 
to ascribe chemotherapy eﬃ  cacy in ER-positive disease 
entirely to false-positive ER results (and, the proportional 
reductions in mortality rates were no greater in ER-
negative than in ER-positive disease). 
ER-positive disease is, however, heterogeneous, and can 
be broadly subdivided into luminal-A (HER2-negative, not 
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tumours. By contrast, widespread mammographic 
screening ﬁ nds many breast cancers with low disease 
burden, low proliferative index, and hence a high 
probability of being endocrine-responsive luminal-A 
tumours. The present meta-analyses were not directly 
informative about the eﬀ ects of chemotherapy on such 
low-risk tumours, but in low-risk ER-positive disease 
treated with eﬀ ective endocrine therapy any further risk 
reduction from adding chemotherapy cannot, in absolute 
terms, be large, and patients not helped by chemotherapy 
are harmed by its toxicity. This includes not only acute 
toxicity and leukaemogenicity but also any persistent 
neurotoxicity and anthracycline cardiotoxicity.18 Longer 
follow-up of the trials will help to assess the eventual risks 
and beneﬁ ts more reliably.
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protein Ki-67), or multigene expression signatures, based 
on tumour RNA proﬁ le. These signatures mainly reﬂ ect 
four groups of genes, which are also associated with ER 
status, progesterone receptor status, HER2 status, and 
proliferation. The joint relevance of such factors to 
prognosis stems mainly from the proliferation-related 
measurements.31–33
Certain trials22,34 have suggested that in ER-positive 
disease the levels of expression of various genes (including 
those related to proliferation) might correlate not only 
with prognosis but also with chemosensitivity, so they 
might help to predict beneﬁ t, or identify some higher-risk 
patients who would gain little from chemotherapy. We 
could not test such hypotheses. Three new trials 
(MINDACT,35  TAILORx,36 RxPONDER37) have included 
more than 10 000 patients with ER-positive disease and 
measurements of gene expression proﬁ le who have been 
randomly allocated chemoendocrine therapy versus the 
same endocrine therapy alone. Their combined results 
will be able to assess reliably the prognostic relevance of 
such measurements (and of other measurements, 
including quantitative immunohisto chemistry30) and will 
help to assess any diﬀ erences in chemotherapy RRs 
between subgroups. 
While awaiting the results of these new trials, it appears 
that ER status, diﬀ erentiation, and the other tumour 
characteristics available for the present meta-analyses had 
little eﬀ ect on the proportional risk reductions with 
taxane-based or anthracycline-based regimens. The more 
eﬀ ective of these regimens oﬀ er on average a one-third 
reduction in 10-year breast cancer mortality, roughly 
independently of the available characteristics. The 
absolute gain from a one-third breast cancer mortality 
reduction depends, however, on the absolute risks without 
chemotherapy (which, for ER-positive disease, are the 
risks remaining with appropriate endocrine therapy). 
Although nodal status and tumour diameter and 
diﬀ erentiation are of little relevance to the proportional 
risk reductions produced by such chemotherapy (and by 
tamoxifen therapy4), they can help in treatment decisions 
as they are strongly predictive of the absolute risk without 
chemotherapy, and hence of the absolute beneﬁ t that 
would be obtained by a one-third reduction in that risk.
Relatively few patients in these trials (and even fewer of 
those with recurrence) had small, well diﬀ erentiated 
For more on the Clinical Trial 
Service Unit (CTSU) see http://
www.ctsu.ox.ac.uk/about/
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